Trial Profile
A Randomized, Double-Blind, Parallel-Group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5 mg in Comparison With Losartan 50 mg Plus Hydrochlorothiazide 12.5 mg in Taiwanese Patients With Mild to Moderate Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Telmisartan/hydrochlorothiazide (Primary) ; Losartan/hydrochlorothiazide
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 18 Nov 2013 Planned number of patients changed from 40 to 31 as reported by ClinicalTrials.gov.
- 22 Jun 2007 New trial record.